Consequently, there may be a growing need to test innovative metabolism-driven approaches that target diverse elements of glioma metabolism, including glutamate-glutamine metabolism, for example, the utilization of a systemic glutaminases inhibitors therapy. This evidence concerns the gene GLS and central nervous system cancer.